NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost
July 18th 2025The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.
Read More
The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.
Read More
The National Comprehensive Cancer Network (NCCN) has updated its ovarian cancer guidelines version 3.2025 to recommend niraparib as maintenance therapy for patients with BRCA wild-type or homologous recombination (HR)–deficiency who did not receive bevacizumab during primary treatment.
Read More
Psychiatric Medication Adherence in Patients Experiencing Homelessness
Unique barriers can lead to psychiatric medication adherence rates as low as 26%.
Read More